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Abstract
Background—Several randomized controlled trials (RCT) have reported no difference in long-
term mortality between coronary artery bypass grafting (CABG) and percutaneous coronary
intervention (PCI). The purpose of this pooled observational analysis was to compare recent
retrospective studies examining long-term survival of patients with multi-vessel coronary artery
disease undergoing CABG and PCI.
Methodology—We searched Medline for observational studies comparing long-term (>1 year)
survival between CABG and PCI for the treatment of multi-vessel coronary artery disease over the
past 10 years.
Results—Eight studies met inclusion criteria. A total of 306,868 patients (155,502 CABG;
151,366 PCI) were identified. Follow-up ranged from 1 to 8 years. Mantel-Haenszel combined
hazard ratios (HR) for mortality demonstrated a protective benefit of CABG compared with PCI
(HR=0.77, 95%CI=0.75–0.79).
Conclusion—These findings suggest a long-term survival advantage for CABG compared with
PCI in patients with multi-vessel coronary artery disease.
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1. INTRODUCTION
Coronary artery disease (CAD) is the cause of 1 in 6 deaths in the U.S. with 785,000
Americans experiencing a new myocardial infarction (MI) and 470,000 experiencing a
recurrent event annually [1]. Current therapies for CAD are aimed at reducing myocardial
oxygen demand and improving blood flow to poorly perfused myocardium [2].
Revascularization can be achieved with either percutaneous coronary intervention (PCI) or
coronary artery bypass grafting (CABG). Both methods provide acceptable symptomatic
relief. PCI is an alternative to CABG for patients with clinically stable CAD that do not have
left main disease and also in cases of acute coronary syndrome (ACS) and/or MI. The
usefulness of PCI is less certain in patients with multi-vessel CAD [3].
Several randomized controlled trials (RCT) have compared long-term outcomes between
CABG and PCI in patients with multi-vessel CAD [4–6]. These studies reported no
difference in long-term survival between CABG and PCI. However, RCTs often have
narrow selection criteria resulting in limited external validity. The purpose of this analysis
was to compare long-term survival of CABG versus PCI by examining retrospective studies
and to contrast the results with current RCTs.
2. MATERIALS AND METHODS
A Medline search from October 2002 to October 2012 included the following keywords:
‘percutaneous coronary intervention’, ‘coronary artery bypass grafting’, ‘comparison’,
‘multi-vessel’, ‘left-main coronary artery’, ‘stent’, ‘CABG’, and ‘PCI’. Reference lists of
articles were reviewed for additional papers. Additionally, we performed a manual search of
the table of contents of journals known to publish relevant content and contacted key
researchers in the field to inquire about manuscripts in-press.
Inclusion criteria included the following: 1) Studies published in English with full text
available; 2) Retrospective comparisons between CABG and PCI; 3) > 1 year of follow-up;
and 4) multi-vessel CAD. Exclusion criteria included: 1) ACS/MI within 24 hours of
intervention; 2) left main coronary artery disease (LMCA); 3) RCTs; and 4) studies with the
main goal of a specific subpopulation comparison. Review articles, editorials, and other non-
peer reviewed manuscripts or abstracts were excluded. Studies also were assessed for
scientific rigor (e.g., peer reviewed, impact factor for journal), inclusion of relevant
independent and outcome-related variables, appropriate sample size, statistical heterogeneity
of results, validity (internal, external), similarity of hypotheses across studies, evidence of a
sufficient knowledge base for statistical integration, and consistency of evidence. A scoping
review was undertaken as a means of refining the specific question for the systematic
integration of the studies [7]. Quality of manuscripts was assessed using a domain-based
evaluation [8]. We considered studies of greater than 1 year to be “long-term.”
Two reviewers independently conducted literature searches and discrepancies were resolved
by consensus. Abstracts of relevant articles were evaluated for inclusion in this study. Data
concerning study characteristics and comorbid conditions were recorded.
Source information was tabulated for all studies including, publication year, country of data
collection, report type, and language in which the study was published. Statistical analyses
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were conducted using SAS® Software (Version 9.3, Cary, NC). Hazard ratios (HR) and 95%
confidence intervals (CI)were individually plotted to visualize differences between studies.
Summary HRsand95%CIswere computed by adapting standard Mantel-Haenszel (M-H)
methods for determining weighted log-normal relative effect measures [9]. Homogeneity of
HRs was tested using Tarone’s approximate score method [10]. Although unpublished
studies were not included in the current analysis, we collected basic information on these
studies when available to help determine possible publication bias (file-drawer effect). A
methods moment was employed to assess the sensitivity of results to hypothetical
unpublished studies [11].
3. RESULTS AND DISCUSSION
3.1 Results
A total of 424 relevant articles were identified. Fifty-seven articles were selected for further
review based upon their title. Of these, 8 articles met final inclusion criteria. The selection
process is outlined in Fig. 1. Study and patient characteristics and are shown in Tables 1 and
2, respectively.
Our null hypothesis that heterogeneity across studies reflects random fluctuation was not
rejected at the α-level = 0.05 level of statistical significance. Publication bias was not
considered to be important based on a methods moment analysis.
The pooled data included 155,502 (50.7%) CABG patients and 151,366 (49.3%) PCI
patients. The summary M-H HR was 0.77 (95%CI=0.75–0.79) (Fig. 2). Exclusion of the
largest study did not substantively change results (HR=0.74, 95%CI=0.71–0.77).
3.2 DISCUSSION
To our knowledge, this is the first analysis to evaluate the long-term survival of patients who
underwent either CABG or PCI for the treatment of multi-vessel CAD from observational
studies. Our results suggest that patients undergoing CABG have increased long-term
survival compared with PCI.
Generally, RCTs are considered to be the best evidence when comparing the efficacy of
treatment groups while retrospective studies, which are prone to recall and selection bias, are
believed to be less convincing than prospective trials [20]. However, RCTs have known
barriers to patient participation and also may not generalize to the population at-large due to
narrow selection criteria [21,22]. For example, the poor, minorities, females, and the elderly
often are underrepresented in many clinical trials [23].
Our results are consistent with 2 recent clinical trials. In the SYNTAX trial, 3-year major
adverse cardiac and cerebrovascular events (MACCE) remained significantly increased for
PCI compared with CABG in patients with multi-vessel CAD [4]. However, this study did
not specifically examine mortality as the primary endpoint. The FREEDOM trial, which
enrolled 1,900 patients at 140 international centers, reported reduced mortality among
CABG-treated patients compared with PCI [24]. In contrast to the current analysis, the
FREEDOM trial was limited to diabetic patients.
3.2.1 Limitations—We did not have access to the source data for any of the studies used
in this analysis. The analysis was based on effect sizes and confidence intervals obtained
from published studies. Accordingly, we were unable to use random effect models for
pooling the data [25].
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Another limitation is that the hazard rates between groups were not parallel for all studies
included in our analysis. For example, PCI was observed to have better outcomes in the first
30 days in one study, however, a survival advantage in favor of CABG was observed for the
remaining 4 years of the study [19].
Analyses combining studies cannot improve the quality or reporting of the original studies
[26]. Variability between studies in reporting preoperative comorbidities, demographics, and
outcome measures limits the comparative ability of such analyses. Selection bias also may
be a limitation of this pooled analysis. One study in our analysis, comprising 62% of the
overall sample, potentially may have marginalized the impact of smaller studies [19].
Furthermore, the heterogeneity of some studies included may have limited the
interpretability of our findings. However, our results remained statistically significant after
excluding this study. An inherent weakness of the current study is that patients were
clinically different before their respective revascularization procedure.
No differentiation was made between patients receiving drug-eluting stents (DES) and bare
metal stents (BMS). DES were introduced in 2003 and their use peaked to account for 90%
of PCI procedures in 2005 [27]. The studies used in this analysis were conducted during
different time periods in which this technology may have varied. Additionally, we were
unable to separate cardiac mortality from total mortality due to inconsistencies in the
reporting of this variable across studies.
Some of the included studies were very large and their confidence intervals were narrow,
making almost all differences statistically significant. However, the smallest study was not
statistically significant and was the only study with a HR > 1. Because statistical
significance is influenced by sample size, the results of a large study can be statistically
significant without being clinically important and vice versa. The methods that we used did
not distinguish between statistical and clinical significance.
4. CONCLUSION
Results from this pooled analysis of observational studies suggest that CABG is associated
with increased survival compared with PCI for patients with multi-vessel CAD. Recent
RCTs also have observed similar findings in specific populations (e.g., diabetics and patients
with high SYNTAX scores). A motivation for our study was that RCTs typically are
conducted in highly selected populations. Thus, it is important to understand how mortality
would compare for the general population of people who receive CABG and PCI. However,
we still recognize that results from RCTs represent a higher level of evidence than
observational studies due to the ability of randomization to render compared groups similar
at baseline. Future RCTs comparing revascularization procedures may benefit by selecting a
broader range of patients more reflective of the general CAD population, and including
minorities, persons of low socioeconomic status, and females. Furthermore, our study
highlights the limitation of completely relying on RCTs to evaluate the efficacy of
cardiovascular interventions.
The degree to which inferences may be drawn depends on both internal and external
validity. Internal validity for a RCT is based on the integrity of methods used to select study
participants, collect information, and conduct analyses, and is a building block for external
validity [28]. Apart from sampling error, RCTs strive to select participants in such a manner
that differences between the index and reference groups are attributed only to the
hypothesized effect under investigation [28]. On the other hand, a study is externally valid if
unbiased inferences can be drawn beyond the extent of the study population examined. The
pooled results of the observational studies used in this current analysis, which included
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patients with varying CAD severity and demographic backgrounds, satisfy external validity
criteria. In contrast, this may be limited in some RCTs.
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Fig. 1. Searchcriteria
LMCA=left main coronary artery; RCT=randomized controlled trial.
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Fig. 2. Forest plot reflecting effect of CABG on total mortality compared with PCI
Forest Plot reflects HRs and 95%CIs for each individual study included in this meta-
analysis. †Estimates were pooled from within the study. HR < 1 reflects a survival benefit
for CABG; HR > 1 reflects a survival benefit for PCI. CABG=coronary artery bypass
grafting; CI=confidence interval; PCI=percutaneous coronary intervention; HR=hazard
ratio.
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